Rania A. Elrashidy, M. Asker, H. Mohamed
Jun 1, 2012
Citations
0
Influential Citations
7
Citations
Quality indicators
Journal
Journal of Pharmacy and Pharmacology
Abstract
Objectives Aliskiren is the first in a new class of orally active direct renin inhibitors, approved for the treatment of hypertension. However, the efficacy of aliskiren in diabetic cardiovascular complications remains to be defined. This study aimed to test the hypothesis that aliskiren may enhance the beneficial effects of pioglitazone against cardiovascular injury associated with diabetic nephropathy.